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Introduction
Hand, foot, and mouth disease (HFMD) is a viral 
and febrile disease frequently seen in children, gener-
ally presenting with a mild course and accompanied by 
oral rash and rashes on palmar surfaces of hand and 
feet (Kliegman and Geme 2015). Cases of HFMD are 
seen all over the world; however, epidemics with serious 
complications that result in deaths are reported mostly 
from Western Pacific Region countries (WHO 2011). 
Enterovirus A species are responsible for more than 90% 
of HFMD cases. Coxsackievirus A (CV-A) 2, 3, 5, 6, 7, 
8, 10, 12, 14, 16, and enterovirus A71 (EV-A71) belong 
to this group. It is known that epidemics are induced 
by CV-A16 and EV-A71, while other enteroviruses may 
cause sporadic cases (Mao et al. 2014; Bian et al. 2015).
CV-A6 was identified, for the first time, as the caus-
ative agent for HFMD in an epidemic that emerged in 
Finland in 2008 (Österback et al. 2009). Following this, 
the identification of CV-A6 as the major causative agent 
for HFMD epidemics continued to occur in France, 
Spain and other European countries in 2009–2011 
(Bracho et al. 2011; Mirand et al. 2012). HFMD epidem-
ics caused by CV-A6 were also reported in the West-
ern Pacific Region and the Americas after 2009 (CDC 
2012; Chen et al. 2012; Fujimoto et al. 2012; Fonseca 
et al. 2014; Han et al. 2014; Hu et al. 2015). More severe 
clinical course and widespread skin rashes were seen in 
cases caused by CV-A6, different from typical HFMD 
(Romero 2017).
Cases with no severe clinical course can be diag-
nosed with clinical findings without the need for 
microbiological diagnostic tests. However, certain sero-
types may lead to severe disease (Romero 2017). Sero-
types may vary within and among countries. Therefore, 
determination of the causative serotype is important 
for public health as well as for the design and imple-
mentation of the preventive measures. Recent increases 
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in movements of people between countries and conti-
nents could be influential in the spread of different viral 
serotypes. Full identification of the causative organism 
could also provide information for the vaccine develop-
ment studies in addition to its epidemiological impor-
tance (WHO 2011).
The published research on HFMD in Turkey has 
been generally towards the clinical aspects of the dis-
ease (Ekinci et al. 2013; Demirhan et al. 2016; Bucak 
et al. 2017). Apart from a single case study, no detailed 
investigations on the viral agent itself have been con-
ducted (Kiratli et al. 2017). In this investigation, we 




Patient Selection. Our study cohort consisted of 
children applied to the outpatient clinics of the Pedi-
atric Infectious Disease Department of Bezmialem 
Vakif University Hospital between January 2015 and 
November 2017. These consecutive patients were 
selected who complained of fever and rash on the 
hands, mouths or on the body including the legs (Fig. 1, 
2 and 3) and who were later clinically diagnosed with 
HFMD. An approval from Bezmialem Vakıf Univer-
sity Ethics Committee for Experimentation Invol- 
ving Human Subjects was obtained before the study 
and informed consent was obtained from all families 
of the subjects.
Sample Collection and Storage. Samples were 
taken from at least two lesions in oral mucosa or trunk 
of patients with clinical symptoms of HFMD. Sterile 
cotton swabs wetted with saline (0.9% NaCl) were 
used for sampling. The samples were stored at –80°C 
in 1.5 ml sterile tubes containing phosphate buffered 
saline (PBS) until further processed.
RNA isolation. Direct-zol RNA MiniPrep Kit (Zymo 
Research, Irvine, CA, USA) was used for nucleic acid 
extraction directly from patient samples and from 
supernatants obtained after viral culture. Manufacturer’s 
instructions were followed for the entire procedure.
Reverse transcription. SensiFAST cDNA Synthesis 
Kit (Bioline, London, UK) was used to synthesize cDNA 
from isolated viral RNAs using random primers and the 
manufacturer’s instructions were followed at all steps. 
cDNA was purified from reverse transcription products 
with Zymo Research DNA Clean & Concentrator™-5 
kit in accordance with the manufacturer’s instructions.
Designing primers and PCR. Pan-enterovirus 
primers specific to the Enterovirus genus targeting 
5’UTR were designed for nested-PCR on basis of pre-
viously published studies (Ge et al. 2013). In addition, 
specific primers targeting VP1 gene were used for 
EV-A71 and CV-A16 (Table I). A commercial kit (Illus-
tra™ Hot Start Master Mix, GE Healthcare, Bucking-
hamshire, UK) was used for PCR. The reaction mixture 
contained 0.5 µmol forward primer, 0.5 µmol reverse 
primer, 1 µl (1–4 µg/µl) post clean-up purified cDNA, 
and 22 µl DNase-RNase free water added to the mas-
ter mix kept ready in PCR tubes. Veriti® thermal cycler 
(Applied Biosystems, Foster City, CA, USA), was pro-
grammed as 94°C for 3 min initial incubation, 30 cycles 
of 94°C for 30 sec, 59°C for 30 sec, 72°C for 30 sec and 
72°C for 5 min in order to amplify the Pan-EV, CV-A16 
and EV-A71 specific products.
Fig. 1. Patients with typical lesions on the hands.
Fig. 3. Patient with generalized lesions on the legs.
Fig. 2. Patients with mouth ulcers.
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The amplification products and the 100 bp marker 
were loaded into 1.5% agarose gel, electrophoresed 
for 40 minutes under 80 V, and analyzed in Molecular 
Imager Gel Doc XR System (BioRad, Hercules, CA, 
U.S.A.) imaging device.
Cell culture. Vero E6 cells were cultured in vitro with 
DMEM (Gibco, Thermo Fisher Scientific, Waltham, 
MA, USA) containing 10% fetal bovine serum (Gibco) 
in 5% CO2 medium at 37°C. Samples were filtered 
through 0.45 µm filters and then added to monolayers 
of Vero E6 cell cultures. The infected cells were exam-
ined after 3 days of incubation for evaluation of Entero-
virus specific cytopathic effects. Reverse-transcription 
PCR was performed with cell culture supernatants to 
confirm the PCR results of the patient samples.
Sanger sequencing and phylogenetic analysis. The 
sequencing of the amplified product was carried out by 
the Sentegen Biyotek (Ankara, Turkey) to determine the 
serotype of Enterovirus detected in the samples.
The sequences of PCR products were assembled and 
edited using BioEdit version 7.0.5 (http://www.mbio.
ncsu.edu/BioEdit/bioedit.html). This sequence was 
compared with the sequences deposited in GenBank 
of the National Center for Biotechnology Informa-
tion (NCBI) by means of the BLASTN 2.2.19 option. 
The consensus sequence was compiled in a FASTA file 
for the phylogenetic analysis and aligned with the 
Clustal W 1.8.1. profile mode included in the Mega 4.0.2 
(https://www.megasoftware.net/mega4/) software.
Results
Eleven of 27 children included in the study were 
female and 16 were male. The ages ranged from 
4 months to 9 years, and 21 of the 27 children were 
aged between 1 and 3 years (78%). Eighteen of the 
patients (67%) applied to the hospital during the sum-
mer months. In the cohorts, neither systemic blisters 
nor high fever was noted. None of our patients needed 
hospitalization. There were no severe complications 
such as meningitis and encephalitis. Only three of 
27 patients applied to the hospital with nail shedding 
after the recovery period of approximately six weeks.
A total of 27 patient samples, 15 from the 2015–2016 
season and 12 from 2017, were included in the study. 
The nested PCR results of 12 patients, sampled in 2015–
2016, revealed products with a length of 530 and 389 bp 
(Fig. 4 and 5) that corresponded to the pan-enterovirus 
outer and inner primers, respectively. This finding was 
interpreted as proof of the Enterovirus content in the 
samples. No positive results were observed after PCR 
performed with the species-specific primers targeting 
CV-A16 and EV-A71 viruses. To confirm the presence 
of enteroviral genetic material, all 12 PCR positive 









Primers used for PCR.
Target Serotype Orientation Sequence
Fig. 5. The samples were subjected to the pan-enterovirus spe-
cific nested PCR with inner primers where 389 bp products were 
amplified. Left to right, line 1: 100 bp marker, lines 2 to 5: HFM-2 
to HFM-5, line 6: HFM-7, line 7: HFM-9, lines 8 to 14: HFM-10 
to HFM-16.
Fig. 4. The samples were subjected to the pan-enterovirus spe-
cific nested PCR with outer primers where 530 bp products were 
amplified. Left to right, line 1: 100 bp marker, lines 2 to 5: HFM-2 
to HFM-5, line 6: HFM-7, line 7: HFM-9, lines 8 to 14: HFM-10 
to HFM-16.
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products were sequenced. Sequencing revealed that 
nine of these samples were consistent with the CV-A6 
sequences but the remaining samples were not (Table II). 
Afterward, a confirmatory species-specific PCR affir-
med that the samples were indeed CV-A6 (Fig. 6).
ing without serotype-specific PCR for EV-A71 and 
CV-A16, since the previous samples were negative. 
Three of the seven samples were CV-A16 according to 
the results of sequencing (Fig. 7).
All the samples were inoculated into the Vero E6 cell 
line and characteristic cytopathic effects were noticed 
after 3-days incubation. The supernatant samples were 
collected and the PCR test was carried out with pan-
enterovirus primers (data not shown). It was noticed 
that the results were compatible with the PCR per-
formed directly from the patient samples.
Discussion
Hand, foot, and mouth disease epidemics are mostly 
caused by EV-A71 and CV-A16. Recently, CV-A6 has 
been identified as the agent of epidemics causing severe 
forms of the disease with general skin involvement. Sim-
ilar epidemics that started in Finland in 2008 were also 
reported from Singapore in 2009, France and Taiwan in 
2010, and the USA, Cuba, Spain, Japan, and China in 
2011 (Bian et al. 2015). In this study, CV-A6 was found 
to be the causative agent in 75% of the cases what was 
confirmed by sequencing (Table III). This result is con- 
sistent with the current literature that reports an increase 
HFM-2 153 F/ 541 R Coxsackievirus A6 99%
HFM-5 153 F/ 541 R Coxsackievirus A6 99%
HFM-9 153 F/ 541 R Coxsackievirus A6 99%
HFM-10 153 F/ 541 R Coxsackievirus A6 99%
HFM-11 153 F/ 541 R Coxsackievirus A6 99%
HFM-12 153 F/ 541 R Coxsackievirus A6 99%
HFM-14 153 F/ 541 R Coxsackievirus A6 99%
HFM-15 153 F/ 541 R Coxsackievirus A6 99%
HFM-16 153 F/ 541 R Coxsackievirus A6 99%
HFM24 153 F/ 541 R Coxsackievirus A16 99%
HFM25 153 F/ 541 R Coxsackievirus A16 99%
HFM26 153 F/ 541 R Coxsackievirus A16 97%
Table II
Phylogenetic identities of the coxsackievirus A isolates,







2015–2016 15 12 9 0
2017 12 7 0 3
Total 27 19 9 3
Table III








Fig. 6. CV-A6 specific primers amplified products of approxi-
mately 645 bp.
Twelve patient samples from 2017, were amplified 
by PCR and seven samples were positive for Enterovi-
rus. These samples were directly subjected to sequenc-
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in CV-A6 incidence (Bian et al. 2015). HFMD is not 
a mandatory disease to report to public health authori-
ties in Turkey. Therefore, complete data on the causative 
agents of the cases throughout the country is not yet 
known. Only a single case study identifying the causative 
agent was reported from Turkey (Kiratli et al. 2017). In 
that study, the identification of CV-16 in a 39 years old 
male patient was performed. The present study identi-
fied CV-A16 in 25% of the pediatric samples (Table III). 
A study conducted in China between 2011 and 2015 on 
2130 samples positive for Enterovirus demonstrated that 
CV-A16 was identified in 32%, and EV-A71 – in 30% of 
the samples (Sun et al. 2017). It has been reported that 
EV-A71 infections may lead to neurological complica-
tions (e.g. aseptic meningitis, acute flaccid paralysis, and 
brainstem encephalitis), and mortality. All of the cases in 
our study were from outpatient services and no EV-A71 
was identified in any patients. The literature reported 
severe cases with CV-A6 but none of our patients had 
a complicated course of the disease and needed hospi-
talization (Yang et al. 2014). Another clinical feature of 
CV-A6 is onychomadesis, (Wei et al. 2011) and in our 
cohorts, only one of the confirmed CV-A6 cases was 
re-admitted to the hospital at the 6th week after the dis-
charge with complaints of onychomadesis.
The frequency of HFMD emergences peak twice in 
a year in countries with a tropical climate; however, it 
can be observed throughout the year. It exhibits a sin-
gle annual rise in summer or fall in countries located 
at higher latitudes (Blomqvist et al. 2010; Huang et al. 
2015; Wang et al. 2017). In Turkey, individual studies 
showed that the frequency of HFMD rises during sum-
mer (Topkarcı 2013; Uğraş et al. 2014; Yorulmaz and 
Onat 2017). In parallel with the previous research, in 
the present study, it has been observed that the majority 
of HFMD cases (67%) applied to our hospital during 
summer months.
Hand, foot, and mouth disease frequently affects 
children under the age of 5. Previous studies show that 
more than half of the individuals affected by epidemics 
were aged between 1 and 3 years (Montes et al. 2013; 
Huang et al. 2015). Seventy-eight percent of 27 children 
included in the current study was aged between 1 and 
3 years. Epidemiological studies investigating HFMD 
have shown that the incidence is 1.5–2  times higher 
among boys compared to girls (Huang et al. 2015; Sun 
et al. 2017). In this study, similarly, the ratio of boys/
girls was 16/11.
One of the limitations of the current study is that 
our cohorts were from a single city and the numbers 
of the patient were rather small. Therefore, our result 
might not reflect the overall HFMD epidemiology of 
all country. Secondly, only 12 sequencing results could 
be used to make the evolutionary trees to establish the 
Fig. 7. Phylogenetic analysis of clinical isolates. Phylogenetic analysis of coxsackievirus A6 nucleotide sequences that were obtained 
using 153F ve 541R primers, showed the relationships between the clinical CV-A6 and the CV-A16 isolate selected from the GenBank. 
A  scale bar indicates branch distances. The phylogenetic tree was constructed using neighbour-joining method and validated with 
1000 pseudo-replicates. Poliovirus (NC 002058.3) was selected as out-group.
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relationship of the CV-A6, or CV-A16 in Turkey in rela-
tion to others in the world. Therefore further studies 
including samples from various regions of Turkey with 
a larger sampling might shed a better light on the dis-
semination as well as the phylogenetic relationships of 
these viral agents. Nevertheless, the data presented in 
the current study reports for the first time a detailed 
investigation about the presence of previously unno-
ticed serotypes on an important public health agent.
Geographically, Turkey acts as a gateway between 
Asia and Europe, and receives an influx of tourists from 
various countries across the world during summer 
months, the time that the incidence of HFMD peaks. 
Therefore, the establishment of a national surveillance 
system for HFMD and identification of causative sero-
type agents are important from an epidemiological 
point of view as well as for the planning and execu-
tion of preventive measures including vaccination. Our 
investigation and reporting might be useful in guiding 
these efforts.
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